Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neuroendocrine Tumors 4 Serotonin Syndrome 2 Carcinoid Tumor 2 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors in Lung 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1 Acromegaly 1

Interventions

Docetaxel 43 Prednisone 42 Radiotherapy 41 Goserelin 39 Leuprolide 37 bicalutamide 35 enzalutamide 25 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 24 Androgen Antagonists 22 Flutamide 19 Triptorelin Pamoate 17 apalutamide 15 Zoledronic Acid 12 Gonadotropin-Releasing Hormone 12 Abiraterone Acetate 12 gallium 68 PSMA-11 11 abiraterone 11 Radiation 11 Magnetic Resonance Spectroscopy 11 Prednisolone 9 Estramustine 8 Dexamethasone 8 Specimen Handling 7 Chemotherapy, Adjuvant 7 Buserelin 7 orteronel 6 luprolide acetate gel depot 6 darolutamide 6 cabazitaxel 6 Standard of Care 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡